Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - antibacterials sisteminio naudojimo, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. reikėtų atsižvelgti į oficialius nurodymus, kaip tinkamai naudoti antibakterinių veiksnių.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

pfizer europe ma eeig  - pegfilgrastimas - neutropenija - immunostimulants, - neutropenija ir febrili neutropenija sergantiems suaugusiesiems pasireiškimo trukmės mažinimas pacientams, kurių onkologinės ligos (išskyrus lėtinį mieloidinę leukemiją ir mielodisplazinį sindromą).

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

glaxosmithkline lietuva, uab - ceftazidimas pentahidratas - milteliai injekciniam ar infuziniam tirpalui - 2 g; 1 g; 3 g; 500 mg - ceftazidime

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

bausch + lomb ireland limited - cefuroksimas - milteliai injekciniam tirpalui - 50 mg - cefuroxime

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

instituto grifols s.a. - fostamatinib dinatrio - trombocitopenija - kiti sisteminės hemostatics - tavlesse fluorouracilu ir folino lėtinių imuninė trombocitopenija (ipp) suaugusių pacientų, kuriems yra ugniai atsparios kitiems gydymo.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

esteve pharmaceuticals gmbh - terizidonas - kietosios kapsulės - 250 mg - terizidone

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

krka, d.d., novo mesto - tert-butilamino perindoprilis/amlodipinas - tabletės - 8 mg/5 mg; 4 mg/10 mg; 4 mg/5 mg; 8 mg/10 mg - perindopril and amlodipine

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivakaftoras - cistinė fibrozė - kiti kvėpavimo sistemos produktai - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 ir 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 ir 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

egis pharmaceuticals plc - rozuvastatinas/ramiprilis - kietosios kapsulės - 10 mg/5 mg - rosuvastatin and ramipril

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

egis pharmaceuticals plc - rozuvastatinas/ramiprilis - kietosios kapsulės - 20 mg/5 mg - rosuvastatin and ramipril